Afinitor fails Phase III gastric cancer trial
This article was originally published in Scrip
Novartis's mTOR inhibitor everolimus (marketed as Afinitor) has failed to meet the primary endpoint in a Phase III study in advanced gastric cancer. The company had previously been hoping to file for its approval in this indication this year, having already obtained US and EU approval for its use in kidney cancer and neuroendocrine tumours of pancreatic origin. It had obtained orphan drug status in the gastric indication in both the EU and US last year. Novartis is also hoping to gain FDA and EMA approval of Afinitor in advanced ER+/HER2- breast cancer this year.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.